Duration of response per the investigator following treatment with brentuximab vedotin
| . | All patients (N = 102) . |
|---|---|
| Objective response according to the investigator, n (%) | 73 (72) |
| CR, n (%) | 34 (33) |
| PR, n (%) | 39 (38) |
| Duration of response for patients with CR, months | |
| Median | NE |
| 95% CI | 20.5, NE |
| Duration of objective response, months | |
| Median | 11.2 |
| 95% CI | 7.7, 18.7 |
| . | All patients (N = 102) . |
|---|---|
| Objective response according to the investigator, n (%) | 73 (72) |
| CR, n (%) | 34 (33) |
| PR, n (%) | 39 (38) |
| Duration of response for patients with CR, months | |
| Median | NE |
| 95% CI | 20.5, NE |
| Duration of objective response, months | |
| Median | 11.2 |
| 95% CI | 7.7, 18.7 |
Duration of response is calculated from the earliest occurrence of either CR or PR.
NE, not estimable.